CAR-T cell exhaustion in B cell lymphoma: Current status, mechanisms, and potential solutions.
Chimeric antigen receptor T cell (CAR-T) therapy represents a revolutionary approach in the treatment of refractory or relapsed hematological malignancies including lymphoma.
APA
Zhao R, Xia J, et al. (2026). CAR-T cell exhaustion in B cell lymphoma: Current status, mechanisms, and potential solutions.. Molecular therapy. Oncology, 34(1), 201099. https://doi.org/10.1016/j.omton.2025.201099
MLA
Zhao R, et al.. "CAR-T cell exhaustion in B cell lymphoma: Current status, mechanisms, and potential solutions.." Molecular therapy. Oncology, vol. 34, no. 1, 2026, pp. 201099.
PMID
41502492
Abstract
Chimeric antigen receptor T cell (CAR-T) therapy represents a revolutionary approach in the treatment of refractory or relapsed hematological malignancies including lymphoma. Despite its efficacy, a significant subset of patients experiences disease progression or relapse after initial response, and CAR-T cell exhaustion in the tumor microenvironment (TME) is a critical cause for the unsatisfactory responses. This review discusses the current situation of CAR-T therapies in the clinical treatment of lymphoma patients, the mechanisms of CAR-T cell exhaustion, and potential strategies to overcome CAR-T cell exhaustion, thereby bringing hope to improve therapeutic outcomes for lymphoma patients.
같은 제1저자의 인용 많은 논문 (5)
- Application of Paranasal Augmentation Rhinoplasty in Asians With Midfacial Concavity.
- Effects of Functional Rhinoplasty on Nasal Obstruction: A Meta-Analysis.
- A multiple imputation approach in enhancing causal inference for overall survival in randomized controlled trials with crossover.
- Sub-Nanometer PtSn Interlayer Tuning Ligand and Strain Effects Boosts Oxygen Reduction Electrocatalysis.
- High-Fat Diet Promotes Glycolysis in Hepatocellular Carcinoma by Suppressing Hepatic Kisspeptin Signaling in Mice.